Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Gain Therapeutics' Accumulated Expenses fell 3181.57% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 3181.57%. This contributed to the annual value of $1.4 million for FY2024, which is 8960.46% up from last year.
  • As of Q3 2025, Gain Therapeutics' Accumulated Expenses stood at $1.0 million, which was down 3181.57% from $984576.0 recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' Accumulated Expenses ranged from a high of $2.1 million in Q3 2022 and a low of $325079.0 during Q2 2021
  • Moreover, its 5-year median value for Accumulated Expenses was $1.1 million (2024), whereas its average is $1.2 million.
  • Per our database at Business Quant, Gain Therapeutics' Accumulated Expenses skyrocketed by 22927.26% in 2022 and then plummeted by 4350.94% in 2025.
  • Over the past 5 years, Gain Therapeutics' Accumulated Expenses (Quarter) stood at $681770.0 in 2021, then soared by 58.72% to $1.1 million in 2022, then plummeted by 32.86% to $726474.0 in 2023, then surged by 89.6% to $1.4 million in 2024, then fell by 23.96% to $1.0 million in 2025.
  • Its Accumulated Expenses was $1.0 million in Q3 2025, compared to $984576.0 in Q2 2025 and $1.2 million in Q1 2025.